ArticleCureus2021

Long-Term Survival With Pembrolizumab Re-administration After Pseudo-Progression With Immune-Related Interstitial Lung Disease in a Patient With Non-small Cell Lung Cancer.

Koki Nakashima et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.